Kodiak Sciences Inc
Last updated September 27, 2026
Organization details
- Legal name
- Kodiak Sciences Inc
- Former names
- Oligasis, LLC
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Palo Alto
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KOD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001468748
- EIN
- 27-0476525
Board of directors
-
Bassil I. Dahiyat · DirectorSince 2023
-
Charles A. Bancroft · DirectorSince 2023
- Since 2023
- Since 2023
-
Richard S. Levy · DirectorSince 2023
-
Robert Profusek · DirectorSince 2023
-
Taiyin Yang · DirectorSince 2023
-
Victor Perlroth · Director · Chairman and CEOSince 2023
Chief executives
Victor Perlroth
· Chairman and CEO
Dates unknown
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.7%
-
98.7%
-
99.4%
Board connections
5 of this board's directors also sit on 19 other boards.
- via Felix Baker, Julian Baker and Richard S. Levy
- via Felix Baker, Julian Baker and Richard S. Levy
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Robert Profusek
- via Richard S. Levy
- via Robert Profusek
- via Bassil I. Dahiyat
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $60,000,008
- 2 purchases by 1 insider
- Sold, last 12 months
- $2,220,497
- 6 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Option exercise | +30,000 | $1.04 | $31,200 |
| Jun 4, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −25,896 | $34.01 | $880,723 |
| Jun 4, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −4,104 | $34.67 | $142,286 |
| Apr 15, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Option exercise | +28,614 | $1.04 | $29,759 |
| Apr 2, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Option exercise | +30,000 | $1.04 | $31,200 |
| Apr 2, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −12,692 | $39.14 | $496,765 |
| Apr 2, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −12,477 | $40.29 | $502,698 |
| Apr 2, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −4,231 | $40.88 | $172,963 |
| Apr 2, 2026 | BORGESON JOHN A. Officer (Chief Financial Officer) | Open-market sale | −600 | $41.77 | $25,062 |
| Mar 25, 2026 | Victor Perlroth Director, Officer (Chairman and CEO) | Option exercise | +300,000 | $1.04 | $312,000 |
| Dec 26, 2025 | Victor Perlroth Director, Officer (Chairman and CEO) | Gift | −12,500 | — | — |
| Dec 18, 2025 | Baker Brothers Life Sciences LP Director, 10% owner | Open-market purchase | +217,428 | $23.00 | $5,000,844 |
| Dec 18, 2025 | Baker Brothers Life Sciences LP Director, 10% owner | Open-market purchase | +2,391,268 | $23.00 | $54,999,164 |
| Jun 17, 2025 | BORGESON JOHN A. Officer (See Remarks) | Open-market sale | −723 | $3.65 | $2,639 |
| Jun 15, 2025 | BORGESON JOHN A. Officer (See Remarks) | Option exercise | +1,875 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.